Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results